BidaskClub Upgrades Albireo Pharma (NASDAQ:ALBO) to “Hold”

Albireo Pharma (NASDAQ:ALBO) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, BidAskClub reports.

A number of other equities analysts have also weighed in on the company. Cowen reaffirmed a “market perform” rating and set a $99.00 target price (up from $97.00) on shares of United Continental in a research report on Wednesday, April 17th. William Blair reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Monday, July 15th. Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Beyondspring in a research report on Wednesday, July 10th. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Albireo Pharma currently has an average rating of “Buy” and a consensus target price of $54.25.

Shares of ALBO opened at $28.22 on Thursday. Albireo Pharma has a 52-week low of $19.10 and a 52-week high of $38.69. The firm has a 50 day simple moving average of $31.51. The firm has a market capitalization of $354.32 million, a price-to-earnings ratio of -7.16 and a beta of 1.56.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.37) by ($0.02). Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $1.20 million. As a group, sell-side analysts anticipate that Albireo Pharma will post -5.99 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ALBO. Rhumbline Advisers grew its holdings in Albireo Pharma by 40.2% during the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 3,743 shares in the last quarter. Prudential Financial Inc. grew its holdings in Albireo Pharma by 5.6% during the fourth quarter. Prudential Financial Inc. now owns 26,556 shares of the biopharmaceutical company’s stock worth $652,000 after buying an additional 1,404 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Albireo Pharma by 7.2% during the fourth quarter. Bank of New York Mellon Corp now owns 37,552 shares of the biopharmaceutical company’s stock worth $921,000 after buying an additional 2,529 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Albireo Pharma by 40.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 116,223 shares of the biopharmaceutical company’s stock worth $2,850,000 after buying an additional 33,390 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Albireo Pharma by 11.3% during the fourth quarter. Geode Capital Management LLC now owns 97,434 shares of the biopharmaceutical company’s stock worth $2,390,000 after buying an additional 9,922 shares in the last quarter. Institutional investors and hedge funds own 70.42% of the company’s stock.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Trading signals using Bollinger bands

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.